Investment Strategy
The investment seeks capital appreciation. The fund invests primarily in common stocks. It normally invests at least 80% of assets in securities of companies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes and companies that benefit significantly from scientific and technological advances in biotechnology. The fund invests in domestic and foreign issuers. It uses fundamental analysis of factors such as each issuer's financial condition and industry position, as well as market and economic conditions to select investments. The fund is non-diversified.Investment Expenses, Sales Charges, and Fees
Annual Operating Expense
Net Expense Ratio: 0.66%
Average Annual Total Returns
All average annual total returns are reported net of all fees and as of the end of the last quarter. Past performance does not guarantee future results.
| Year | 1 | 3 | 5 | 10 |
Since Inception (12/16/1985) |
|---|---|---|---|---|---|
Total Returns |
-4.29%
|
5.43%
|
6.85%
|
3.26%
|
12.00%
|
Impact of Expenses and Fees
The table below assumes the investor invests $10,000 on the first day of year one and that the original investment earns a continuous 5% return. In addition, it assumes the
investor reinvests all earnings, and makes no additional contributions. The 5% rate of return is hypothetical and used only to illustrate the respective impacts of different fee
amounts on each investment. It is not intended to predict future investment returns.
Calculations are done by the 403bCompare site in an effort to provide a standardized comparison of the impact of all fees associated with an investment option. This includes all
required 403(b) product-level fees, and investment-level fees. For more information on fees or expenses associated with a 403(b) product or investment option, please refer
fees located in Help & Resources .
| If Shares are Redeemed | |||||
|---|---|---|---|---|---|
| End of year |
1
|
5
|
10
|
15
|
20
|
| Total Fees and Charges |
$195
|
$994
|
$2,051
|
$3,185
|
$4,415
|
| If Shares are Not Redeemed | |||||
|---|---|---|---|---|---|
| End of year |
1
|
5
|
10
|
15
|
20
|
| Total Fees and Charges |
$195
|
$994
|
$2,051
|
$3,185
|
$4,415
|